These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 35596010)

  • 1. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
    Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
    Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
    Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
    Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
    Front Immunol; 2022; 13():976107. PubMed ID: 36091006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
    Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
    FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 9. HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells.
    Gu Z; Yang Y; Ma Q; Wang H; Zhao S; Qi Y; Li Y
    Respir Res; 2022 Dec; 23(1):362. PubMed ID: 36536402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
    Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
    Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
    Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
    Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
    Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
    BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma.
    Wang Y; Zhao X; Li J; Wang X; Hu W; Zhang X
    Technol Cancer Res Treat; 2022; 21():15330338221085373. PubMed ID: 35343834
    [No Abstract]   [Full Text] [Related]  

  • 15. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles.
    Dong B; Wu C; Li SH; Huang L; Zhang C; Wu B; Sheng Y; Liu Y; Ye G; Qi Y
    Ann Transl Med; 2021 Sep; 9(18):1465. PubMed ID: 34734017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
    Shen Y; Wang S; Wu Y
    Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
    Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
    Front Immunol; 2021; 12():789914. PubMed ID: 34887874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.